ThinkEquity Lowers Gen-Probe Incorporated to Hold (GPRO)
Shares of Gen-Probe Incorporated traded up 0.02% during mid-day trading on Tuesday, hitting $81.48. Gen-Probe Incorporated has a one year low of $53.92 and a one year high of $86.96. The company has a market cap of $3.662 billion and a P/E ratio of 78.71.
The company last announced its quarterly results on Monday, April 30th. It reported $0.55 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.51 EPS by $0.04. The company’s quarterly revenue was up 7.3% on a year-over-year basis. On average, analysts predict that Gen-Probe Incorporated will post $0.67 earnings per share next quarter.
Other equities research analysts have also recently issued reports about the stock. Analysts at Raymond James (NYSE: RJF) downgraded shares of Gen-Probe Incorporated from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday. Separately, analysts at Piper Jaffray (NYSE: PJC) downgraded shares of Gen-Probe Incorporated from an “overweight” rating to a “neutral” rating in a research note to investors on Monday. Finally, analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Gen-Probe Incorporated from $68.00 to $70.00 in a research note to investors on Monday, April 23rd. They now have an “overweight” rating on the stock.
Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing molecular diagnostic products and services, which are used to diagnose human diseases, screen donated human blood, and ensures transplant compatibility.